Goodrx (NASDAQ: GDRX) recently released its list of the 10 most expensive drugs on the market. Novartis ' (NYSE: NVS) gene therapy Zolgensma remains at the top, but newcomers Eiger Pharmaceuticals (NASDAQ: EIGR) and Y-mAbs Therapeutics (NASDAQ: YMAB) took second and third place with Zokinvy and Danyelza, respectively. In this video from Motley Fool Live , recorded on Mar ch 15 , Fool.com Contributors Brian Orelli and Keith Speights discuss the high-priced drugs and whether the prices are sustainable in the long run.
For further details see:
Are Ultra-High Drug Prices Sustainable?